Suchergebnisse - "Oertel, Stephan"

PubPharm (48)

1

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma : results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

ErratumIn: Ann Hematol. 2014 Oct;93(10):1807

2

Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

3

Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

4

Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

5

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

6

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

7

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study

enthalten in: Annals of hematology | 2014

von Witzens-Harig, M. | Foá, R. | Di Rocco, A. | +10

8

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia : Final analysis of an open-label phase II study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hillmen, P. | Gribben, J. | Follows, G. | +13

9

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2014

von Hillmen, P. | Gribben, J. | Follows, G. | +13

10

Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder

enthalten in: Journal of immunology research | 2014

von Zimmermann, H. | Weiland, T. | Nourse, J. | +9

1
2
3
4
5
Nächster »
[5]